Jinxin Fertility Group Limited

1951

KYG5140J1013

Healthcare Facilities & Services

Delayed Hong Kong S.E. Other stock markets 10:12:05 2024-04-24 pm EDT			5-day change	1st Jan Change
2.5 ^HKD	+0.81%		+8.23%	-25.37%

Mar. 29	Jinxin Fertility Logs 185% Profit Surge in 2023 as Revenue Rises 18%	MT
Mar. 27	Jinxin Fertility Group Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 25 July 2024	CI

Jinxin Fertility Group Limited Proposes Final Dividend for the Year Ended December 31, 2019

May 26, 2020 at 04:42 am EDT

Jinxin Fertility Group Limited proposed final dividend of 6.8 Hong Kong cents per share for the year ended December 31, 2019, at the AGM to be held on June 29, 2020.

Latest news about Jinxin Fertility Group Limited

Jinxin Fertility Logs 185% Profit Surge in 2023 as Revenue Rises 18%	Mar. 29	MT
Jinxin Fertility Group Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 25 July 2024	Mar. 27	CI
Jinxin Fertility Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Jinxin Fertility Group Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023	Mar. 15	CI
Nomura Adjusts Jinxin Fertility Group’s Price Target to HK$6.24 From HK$8.20, Keeps at Buy	Feb. 28	MT
Innovent Biologics Names New CFO	Feb. 05	MT
Jinxin Fertility Group Limited Announces Changes in Address	Jan. 18	CI
Jinxin Fertility CFO Resigns; Successor Named	Jan. 03	MT
Jinxin Fertility Group Limited Announces Change of Chief Financial Officer	Jan. 02	CI
Jinxin Fertility Group Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-29	CI
Nomura Adjusts Jinxin's Price Target to HK$8.20 From HK$8.90, Keeps at Buy	23-07-31	MT
Jinxin Fertility Group Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Jinxin Fertility Group Limited Not Recommends Payment of Final Dividend for the Year Ended December 31, 2022	23-03-30	CI
Nomura Adjusts Jinxin Fertility’s Price Target to HK$8.90 From HK$8.71, Keeps at Buy	23-02-13	MT
Jinxin Fertility Completes Share Issuance, Placement	23-01-17	MT
Jinxin Fertility to Raise HK$1.16 Billion From Share Placement	23-01-04	MT
Jinxin Fertility Group Completes Restructuring	23-01-02	MT
Nomura Adjusts Jinxin Fertility’s Price Target to HK$8.71 From HK$9.23, Keeps at Buy	22-09-01	MT
Jinxin Fertility Group Logs Higher H1 Profit	22-09-01	MT
Jinxin Fertility Group Limited Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-31	CI
Nomura Adjusts Jinxin Fertility Group's Price Target to HK$9.23 From HK$9.80, Keeps at Buy	22-08-09	MT
Jinxin Fertility Group Completes Acquisition of Equity Interests in Kangzhi Hospital, Guangzhou Yunzhicai, Guangzhou Hejia; Shares Climb 6%	22-07-14	MT
Jinxin Fertility Group Limited Declares Final Dividend for the Year Ended December 31, 2021	22-06-28	CI
Jinxin Fertility Group Limited Proposes Final Dividend for the Year Ended December 31, 2021	22-05-26	CI
Nomura Adjusts Jinxin Fertility Group's Price Target to HK$9.8 From HK$12.4, Keeps at Buy	22-03-31	MT

Chart Jinxin Fertility Group Limited

Duration

Period

More charts

Jinxin Fertility Group Limited is a China-based company principally engaged in the provision of assisted reproductive services (ARS). The Company operates its business through three segments. The ARS segment primarily provides its patients with two treatment solutions: artificial insemination (AI) and in vitro fertilization (IVF) technology. The Management Services segment provides management services to Jinjiang IVF Center and Jinxin Fertility Center. The Ancillary Medical Services segment mainly provides medical services in the areas of gynecology, urology and internal medicine through Shenzhen Zhongshan Hospital. The Company mainly operates its business in China and the Unites.

Sector

Healthcare Facilities & Services

Calendar

2024-08-26 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Jinxin Fertility Group Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.294 CNY

Average target price

4.184 CNY

Spread / Average Target

+82.37%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
JINXIN FERTILITY GROUP LIMITED	-25.37%	845M
CVS HEALTH CORPORATION	-14.17%	86.34B
HCA HEALTHCARE, INC.	+17.86%	84.49B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+10.92%	29.68B
LABORATORY CORPORATION OF AMERICA HOLDINGS	-8.51%	17.5B
FRESENIUS SE & CO. KGAA	-2.67%	16.67B
QUEST DIAGNOSTICS INCORPORATED	-0.24%	15.18B
EUROFINS SCIENTIFIC SE	-3.63%	12.71B
FRESENIUS MEDICAL CARE AG	+2.63%	12.53B
PURE HEALTH HOLDING	-30.53%	11.89B

Other Healthcare Facilities & Services